圣诺医药-B(02257)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02257 圣诺医药-B

已收盘 10-06 15:57:29

3.740

-0.005

-0.13%

最高3.740	最低3.740	成交量0.00
今开3.740	昨收3.745	日振幅0.00%
总市值4.19亿	流通市值4.19亿	总股本1.12亿
成交额0.00	换手率0.00%	流通股本1.12亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02257","market":"HK","secType":"STK","nameCN":"圣诺医药-B","latestPrice":3.74,"timestamp":1791273449212,"preClose":3.745,"halted":0,"volume":0,"delay":0,"changeRate":-0.0013351134846461665,"floatShares":112000000,"shares":112000000,"eps":-0.152476,"marketStatus":"已收盘","change":-0.005,"latestTime":"10-06 15:57:29","open":3.74,"high":3.74,"low":3.74,"amount":0,"amplitude":0,"askPrice":3.74,"askSize":3500,"bidPrice":3.62,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-0.742,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791336600000},"marketStatusCode":5,"adr":0,"listingDate":1640793600000,"exchange":"SEHK","adjPreClose":3.745,"openAndCloseTimeList":[[1791250200000,1791259200000],[1791262800000,1791273600000]],"volumeRatio":0,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02257","defaultTab":"news","newsList":[{"id":"1157681211","title":"圣诺医药-B（02257）完成目标公司增资交易 投资前估值5亿元并设估值下调机制","url":"https://stock-news.laohu8.com/highlight/detail?id=1157681211","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157681211?lang=zh_cn&edition=full","pubTime":"2026-10-06 17:07","pubTimestamp":1791277654,"startTime":"0","endTime":"0","summary":"2026年10月6日，圣诺医药-B公告称，投资者已于本公告日期前向目标公司指定银行账户全额缴付认购款，视作出售事项已完成。该交易涉及投资者以投前估值人民币5亿元认购目标公司股权，并获授回购权。公司称，鉴于交易的战略价值，经公平磋商后认定5亿元估值溢价具商业合理性。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136388507","title":"圣诺医药-B9月股份变动月报：股本维持112,157,138股","url":"https://stock-news.laohu8.com/highlight/detail?id=1136388507","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136388507?lang=zh_cn&edition=full","pubTime":"2026-10-06 16:57","pubTimestamp":1791277022,"startTime":"0","endTime":"0","summary":"圣诺医药-B于2026年10月6日发布截至2026年9月30日的月报表。公司注册股本维持230,000,000股，面值每股0.001美元，法定/注册股本总额为230,000美元。当月已发行股份数量依旧为112,157,138股，未有新增发行或回购，库存股份数量保持为0股。本月公司股份期权方面，2022年购股权计划有18,825份期权失效。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669762483","title":"字节、百度与恒瑞、诺和诺德，抢滩AI制药商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2669762483","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669762483?lang=zh_cn&edition=full","pubTime":"2026-09-23 20:01","pubTimestamp":1790164907,"startTime":"0","endTime":"0","summary":"截图来源于港股公告叠加字节跳动将AI制药业务独立拆分设立Anew Labs这一动作，入局AI制药的大厂阵营还在持续扩容。目前，行业已有落地成果佐证AI的前端价值。港股龙头英硅智能的发展路径，展现了当前AI药企的部分商业化现状。截图来源于港股公告这份增速亮眼的财报，证明AI技术具备即时商业变现能力。AI技术模型可以加快新药研发的起点，但从这条赛道跑出来的玩家，大概率是率先实现临床转化与商业化落地的那个。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789979347715387090","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0183","BK4526","LU1820825898.SGD","09888","LU1093756168.USD","LU2580892862.HKD","BK0012","NVOC","BK4077","NVOH","LU2148510915.USD","BK4514","BK0196","BK4614","BK4535","IE00BZ1G4Q59.USD","BIDU","BK4531","BK4543","LU2495084118.USD","THNR","LU1781817850.SGD","LU1997245177.USD","LU1023057109.AUD","LU2097828631.EUR","BK0060","BK4504","LU2328871848.SGD","LU1997244956.HKD","LU1064131003.USD","DRGN","LU2289578879.USD","LU2097828805.USD","BK4588","LU0287142896.SGD","LU2097828714.EUR","BK4552","LU1969619763.USD","NVOX","600276","BK0028","BK4587","BK0188","LU1655091616.SGD","LU2097828557.USD","IE00B0JY6N72.USD","LU1255011170.USD","BK0239","BK4602","BK4548","LU1328615791.USD","LU1997245094.SGD","NVO","LU0154236417.USD","BK4532","LU0359201612.USD","01276","BK4612","LU0359202008.SGD","LU2580892789.USD","LU0405327148.USD","BK4574","LU1093756325.SGD","LU2097828474.EUR","LU0405327494.USD","OZEM","BK4585","BK4579","BIDG","LU2488822045.USD","LU0173614495.USD","KBDU","LU1115378108.SGD","BK1161","BK4007","PPH","LU1064130708.USD","BK4599","IE00BKVL7J92.USD","LU0640798160.USD","LU1146622755.USD","02257","LU1580142542.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125689774","title":"圣诺医药-B更新2026年8月股份变动月报，本月新增243.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1125689774","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125689774?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:12","pubTimestamp":1788426740,"startTime":"0","endTime":"0","summary":"圣诺医药于2026年9月3日发布2026年8月股份变动月报。报告期为2026年8月1日至2026年8月31日，法定股本维持与上期一致，面值为每股0.001美元，总计230,000,000股，对应总额230,000美元。本期普通股发行方面，截至2026年7月底，公司已发行股份为109,721,538股。2022年受限制股份单位计划已终止，但在终止前已授出的部分受限制股份仍处于未归属状态，截至2026年8月31日尚余4,823股未归属。本月报告期末，公司已发行股份总数为112,157,138股，股本较上月增长2,435,600股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662060075","title":"圣诺医药-B(02257)发布中期业绩 股东应占溢利9.1万美元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2662060075","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662060075?lang=zh_cn&edition=full","pubTime":"2026-08-28 20:11","pubTimestamp":1787919116,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B(02257)发布截至2026年6月30日止6个月业绩，该集团期内取得其他收入14万美元，同比增加12.9%;公司拥有人应占溢利9.1万美元，同比扭亏为盈;每股基本盈利0.09美分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148816144","title":"圣诺医药-B2026年上半年营收0美元，经调整后净亏损0.38百万美元，同比收窄约88.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148816144","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148816144?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:44","pubTimestamp":1787917444,"startTime":"0","endTime":"0","summary":"2026年上半年，圣诺医药-B（股票代码：02257）实现营收0美元，和上年同期持平。经调整后净亏损0.38百万美元，相较上年同期的3.39百万美元亏损显著收窄约88.80%。\n本期管理费用为2.15百万美元，较去年同期的2.55百万美元减少约0.40百万美元，降幅约15.70%；研发投入为2.03百万美元，较去年同期的3.05百万美元下降约33.40%。经营活动所用现金净额为4.79百万美元，相较上年同期的4.89百万美元略有改善。整体来看，公司通过简化组织结构和优化成本配置，使得经营效率与研发投入占比持续提升。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺医药-B2026年上半年营收0美元，经调整后净亏损0.38百万美元，同比收窄约88.80%","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662197713","title":"圣诺医药-B(02257.HK)：达冕疫苗(广州)获广州广健医药创新股权投资基金注资3000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662197713","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662197713?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:10","pubTimestamp":1787742657,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["09939","02257","BK1515","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174194157","title":"圣诺医药-B（02257）拟出让5.66%目标公司股权获30百万元注资 并授予回购权","url":"https://stock-news.laohu8.com/highlight/detail?id=1174194157","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174194157?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:05","pubTimestamp":1787742356,"startTime":"0","endTime":"0","summary":"圣诺医药-B（02257）8月26日晚间公告称，其间接非全资附属公司RNAimmune, Inc.（下称“卖方”）已与广州广健医药创新股权投资基金合伙企业（有限合伙）（下称“投资者”）及达冕疫苗（广州）有限公司（下称“目标公司”）签订投资协议。投资者将向目标公司注入现金共计人民币30百万元，其中人民币3百万元计入注册资本，其余人民币27百万元计入资本公积金。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660105127","title":"因2000万美元投资暴雷，圣诺医药将创始人等前高管告上法庭","url":"https://stock-news.laohu8.com/highlight/detail?id=2660105127","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660105127?lang=zh_cn&edition=full","pubTime":"2026-08-17 08:15","pubTimestamp":1786925742,"startTime":"0","endTime":"0","summary":"港股圣诺医药近日公告称，公司及其直接全资附属公司圣诺（香港）有限公司8月14日向香港特别行政区高等法院提交传讯令状，正式起诉其创始人陆阳及另外两名前管理层戴晓畅、叶永基。圣诺医药今年股价走势疲弱，至今大跌45%。此次起诉与一笔约2000万美元的投资有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173842621864.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173842621864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659203281","title":"2000万美元投资亏损，“小核酸第一股”起诉创始人陆阳","url":"https://stock-news.laohu8.com/highlight/detail?id=2659203281","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659203281?lang=zh_cn&edition=full","pubTime":"2026-08-15 11:34","pubTimestamp":1786764840,"startTime":"0","endTime":"0","summary":"因为一笔投资亏损，“小核酸第一股”将创始人告上了法庭。8月14日，圣诺医药（2257.HK）发布公告称，公司及其直接全资附属公司圣诺（香港）有限公司已向香港特别行政区高等法院提交传讯令状，控告集团若干前管理层，包括陆阳、戴晓畅及叶永基。圣诺医药称，公司已指示其法律顾问采取一切必要措施，以维护本集团的合法权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608153842392995.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608153842392995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02257","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191720128","title":"圣诺医药-B（02257）向香港高院提出诉讼　追责前管理层涉约2,000万美元投资","url":"https://stock-news.laohu8.com/highlight/detail?id=1191720128","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191720128?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:06","pubTimestamp":1786712793,"startTime":"0","endTime":"0","summary":"2026年8月14日，圣诺医药-B发布内幕消息公告称，公司及其全资子公司圣诺（香港）有限公司已向香港特别行政区高等法院提交传讯令状，被告为公司若干前管理层成员陆阳博士、戴晓畅博士及叶永基先生。诉讼涉及集团此前对TradArt Flagship Investment SPC独立投资组合作出的本金总额约2,000万美元投资。圣诺医药-B提醒股东及潜在投资者在买卖公司股份时保持审慎。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659513144","title":"圣诺医药-B(02257.HK)已向法院提交传讯令状，控告集团若干前管理层，包括陆阳、戴晓畅及叶永基","url":"https://stock-news.laohu8.com/highlight/detail?id=2659513144","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659513144?lang=zh_cn&edition=full","pubTime":"2026-08-14 21:05","pubTimestamp":1786712723,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172328393","title":"圣诺医药-B将于8月28日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1172328393","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172328393?lang=zh_cn&edition=full","pubTime":"2026-08-14 17:06","pubTimestamp":1786698365,"startTime":"0","endTime":"0","summary":"圣诺医药-B（02257）8月14日发布公告称，公司董事会已排期于2026年8月28日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布事宜。\n公告显示，会议由董事会主席兼执行董事潘洪辉博士主持。\n截至公告披露日，董事会成员包括执行董事潘洪辉博士；非执行董事殷惠军博士；以及独立非执行董事王宇山先生、张鹏博士及卢懿杏女士。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153646416","title":"圣诺医药-B(02257)完成一般授权新股认购 募资约11.3百万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153646416","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153646416?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:06","pubTimestamp":1786525594,"startTime":"0","endTime":"0","summary":"2026年8月12日，圣诺医药-B公告称，公司根据先前于2026年5月23日及6月1日披露的认购协议，已于2026年8月12日完成新股认购交易。– 本次共配发及发行2,435,600股新股份，约占完成后已发行股份总数的2.17%。– 认购价为每股4.69港元。– 认购事项净筹约11.3百万元，拟全部用于集团一般营运资金。– 完成前，公司已发行股份为109,721,538股；完成后增至112,157,138股。公司表示，本次募得资金将增强流动性，支持其日常运营。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190661563","title":"圣诺医药-B：8月12日发行243.56万股新股，涉资约1,142.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190661563","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190661563?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:05","pubTimestamp":1786525558,"startTime":"0","endTime":"0","summary":"圣诺医药-B（股票代码：02257）于2026年8月12日发布翌日披露报表，宣布依据2026年5月23日签署的认购协议，并根据一般授权完成新股份发行。此次增发股票数量为2,435,600股，约占发行前公司已发行股本的2.22%；增发价格为每股4.69港元，合计涉资约1,142.30万港元。\n本次发行完成后，圣诺医药-B已发行股本增至112,157,138股，库藏股数为0股。公司在公告中确认，相关股份发行已获得董事会批准，并遵守了适用上市规则及相关法律规定。该公告由公司秘书袁润廷签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"圣诺医药-B：8月12日发行243.56万股新股，涉资约1,142.30万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161978","title":"圣诺医药-B(02257)完成发行合共243.56万股认购股份 净筹约1130万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161978","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161978?lang=zh_cn&edition=full","pubTime":"2026-08-12 17:01","pubTimestamp":1786525301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，圣诺医药-B(02257)发布公告，认购协议的所有先决条件均已达成，而认购事项已于2026年8月12日完成。合共243.56万股认购股份(占紧随完成后已发行股份数目约2.17%)已根据认购协议的条款及条件，按认购价每股认购股份4.69港元配发及发行予认购人。认购事项所得款项净额约为1130万港元。本集团拟将认购事项所得款项用作其一般营运资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479000.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"圣诺医药-B(02257)完成发行合共243.56万股认购股份 净筹约1130万港元","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168755364","title":"圣诺医药-B7月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1168755364","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168755364?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:47","pubTimestamp":1785923259,"startTime":"0","endTime":"0","summary":"圣诺医药-B于2026年8月5日发布截至2026年7月31日的股份变动月报表。公告显示，公司在本期内已发行股份、注册股本及库藏股份规模均未发生变化。在期权与股权激励方面，2022年购股权计划期末结存110,199份，同比上月底减少609,641份失效期权；本月内未有期权被授出或行使。2026年购股权计划暂无实质行权变化，本月亦无授出或行使记录，但预留可发行上限共计10,972,153份购股权。截至2026年7月31日，公司整体股权结构维持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174608009","title":"圣诺医药-B宣布STP 705医美II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1174608009","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174608009?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:26","pubTimestamp":1785403591,"startTime":"0","endTime":"0","summary":"圣诺医药-B2026年7月30日发布自愿性公告称，其RNA疗法管线项目STP 705用于医美适应症的II期多中心临床试验已完成首名研究参与者首次给药，这是该项目的重要临床里程碑。该II期试验的主要终点为系统性评估STP 705通过局部给药实现靶向皮下脂肪减少的临床疗效；次要评估涵盖安全性、耐受性及局部治疗反应特征。公司在公告中提醒，当前无法保证能够成功开发或最终将STP 705商业化。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655982201","title":"圣诺医药-B(02257.HK)：STP705用于医疗美容的II期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2655982201","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655982201?lang=zh_cn&edition=full","pubTime":"2026-07-30 17:18","pubTimestamp":1785403092,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02257","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164972885","title":"圣诺医药-B（02257.HK）设立外部科学顾问委员会 加强RNAi疗法研发布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1164972885","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164972885?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:05","pubTimestamp":1784624733,"startTime":"0","endTime":"0","summary":"2026年7月21日，圣诺医药-B发布自愿性公告称，已正式成立外部科学顾问委员会，以就集团治疗管线研发项目提供独立且权威的科学指导。新成立的科学顾问委员会由五名跨学科国际专家组成，覆盖RNA递送技术、RNA干扰药物发现、肿瘤学研发、临床转化医学、化学—制造—控制及全球药品监管合规等领域。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02257"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.sirnaomics.com/en/","stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":-0.0145},{"period":"3month","weight":-0.1998},{"period":"6month","weight":-0.458},{"period":"1year","weight":-0.7487},{"period":"ytd","weight":-0.5117}],"compareEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0628},{"period":"3month","weight":0.0231},{"period":"6month","weight":-0.0716},{"period":"1year","weight":-0.1142},{"period":"ytd","weight":-0.062}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Sirnaomics Ltd是一家投资控股公司。该公司及其子公司均为临床阶段生物技术公司，致力于开发和商业化核糖核酸干扰（RNAi）技术及多种疗法。该公司专注于发现和开发针对特定领域尚未满足医疗需求的药物。该公司主要临床候选药物包括STP705和STP707。STP705是一种多靶点siRNA疗法，目前正在推进针对两种肿瘤适应症的临床开发：原位鳞状细胞癌（isSCC）和基底细胞癌（BCC）。STP707是一种静脉注射siRNA疗法，目前正在进行针对多种实体瘤（包括结直肠癌、胰腺癌、肝癌和转移性黑色素瘤）的I期临床试验。该公司正充分利用其双重递送平台，包括多肽纳米颗粒（PNP）和GalAhead。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.131369},{"month":2,"riseRate":0.6,"avgChangeRate":-0.02454},{"month":3,"riseRate":0.2,"avgChangeRate":-0.124827},{"month":4,"riseRate":0.4,"avgChangeRate":-0.031494},{"month":5,"riseRate":0.4,"avgChangeRate":0.01256},{"month":6,"riseRate":0.6,"avgChangeRate":-0.050821},{"month":7,"riseRate":0.6,"avgChangeRate":0.098945},{"month":8,"riseRate":0.2,"avgChangeRate":-0.078309},{"month":9,"riseRate":0.8,"avgChangeRate":0.192592},{"month":10,"riseRate":0,"avgChangeRate":-0.147091},{"month":11,"riseRate":0,"avgChangeRate":-0.082953},{"month":12,"riseRate":0.5,"avgChangeRate":0.008221}],"exchange":"SEHK","name":"圣诺医药-B","nameEN":"SIRNAOMICS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"圣诺医药-B(02257)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供圣诺医药-B(02257)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"圣诺医药-B,02257,圣诺医药-B股票,圣诺医药-B股票老虎,圣诺医药-B股票老虎国际,圣诺医药-B行情,圣诺医药-B股票行情,圣诺医药-B股价,圣诺医药-B股市,圣诺医药-B股票价格,圣诺医药-B股票交易,圣诺医药-B股票购买,圣诺医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"圣诺医药-B(02257)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供圣诺医药-B(02257)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}